Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MRKRNASDAQ:OASMNASDAQ:REPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKRMarker Therapeutics$4.30-0.9%$4.24$0.67▼$9.68$38.23M1.4920,834 shs19,774 shsOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shs101 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKRMarker Therapeutics+0.12%-3.67%+14.08%-24.61%+414.05%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKRMarker Therapeutics1.2683 of 5 stars0.04.00.03.93.01.70.0OASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKRMarker TherapeuticsN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKRMarker Therapeutics$3.31M11.55N/AN/A$2.34 per share1.84OASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKRMarker Therapeutics-$29.93MN/A0.00∞N/A-77.33%-98.22%-62.67%5/21/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKRMarker TherapeuticsN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKRMarker TherapeuticsN/A7.017.01OASMOasmia Pharmaceutical AB (publ)N/A0.800.73REPHRecro Pharma2.273.242.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKRMarker Therapeutics22.39%OASMOasmia Pharmaceutical AB (publ)0.11%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipMRKRMarker Therapeutics24.10%OASMOasmia Pharmaceutical AB (publ)N/AREPHRecro Pharma14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMRKRMarker Therapeutics678.89 million6.75 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionableREPH, OASM, and MRKR HeadlinesSourceHeadlineFuji Pharma Co. Ltd.wsj.com - January 30 at 3:34 PMAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croremoneycontrol.com - November 22 at 10:47 PMRetaining the human element of AI within pharma and healthcarepharmaphorum.com - November 21 at 10:06 AMHere's what Wall Street expects from Recro Pharma's earnings reportmarkets.businessinsider.com - November 7 at 12:00 PMUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitstheguardian.com - August 16 at 1:59 AMMankind Pharma share pricelivemint.com - August 9 at 12:30 PMWhat Wall Street expects from Recro Pharma's earningsmarkets.businessinsider.com - August 9 at 7:25 AMMankind Pharma Ltd (MNKI)investing.com - August 3 at 9:00 AMEversana and Amazon plan generative AI push in pharmapharmaphorum.com - July 30 at 11:21 PMAurobindo Pharma Ltd.ndtv.com - July 25 at 12:39 AMBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsbizjournals.com - June 30 at 12:44 PMPharma reform: Patients can’t afford to wait. Act now.politico.eu - June 13 at 3:41 PMSun Pharma reports "information security incident"; isolates impacted IT assetshealth.economictimes.indiatimes.com - March 9 at 7:26 AMWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLijr.com - March 2 at 12:30 AMAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendmoneycontrol.com - February 17 at 8:43 PMPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusfinancialexpress.com - December 20 at 8:48 AMPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLbenzinga.com - June 24 at 9:08 AMSocietal CDMO Increuters.com - April 20 at 9:24 AMRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformationfinanznachrichten.de - March 22 at 10:51 PMRecro Pharma Rebrands to Societal CDMO Inc.contractpharma.com - March 22 at 5:51 PMIs Recro Pharma (REPH) a Worthy Investment?finance.yahoo.com - March 22 at 8:32 AMRecap: Recro Pharma Q4 Earningsbenzinga.com - March 1 at 11:55 PMRecro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilitiescontractpharma.com - February 23 at 9:51 PMRecro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facilityfinance.yahoo.com - February 23 at 11:18 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMarker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401, which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Recro PharmaNASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.